201 related articles for article (PubMed ID: 36338920)
1. Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis.
Pantano F; Tramontana F; Iuliani M; Leanza G; Simonetti S; Piccoli A; Paviglianiti A; Cortellini A; Spinelli GP; Longo UG; Strollo R; Vincenzi B; Tonini G; Napoli N; Santini D
J Bone Oncol; 2022 Dec; 37():100459. PubMed ID: 36338920
[TBL] [Abstract][Full Text] [Related]
2. Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation.
Gassner T; Chittilappilly C; Pirich T; Neuditschko B; Hackner K; Lind J; Aksoy O; Graichen U; Klee S; Herzog F; Wiesner C; Errhalt P; Pecherstorfer M; Podar K; Vallet S
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702145
[TBL] [Abstract][Full Text] [Related]
3. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
4. Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer.
Lumachi F; Santeufemia DA; Del Conte A; Mazza F; Tozzoli R; Chiara GB; Basso SM
Anticancer Res; 2013 Jun; 33(6):2593-6. PubMed ID: 23749913
[TBL] [Abstract][Full Text] [Related]
5. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
6. Value of C-telopeptide-cross-linked Type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen Type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors.
Zhao H; Han KL; Wang ZY; Chen Y; Li HT; Zeng JL; Shen Z; Yao Y
Med Sci Monit; 2011 Nov; 17(11):CR626-633. PubMed ID: 22037741
[TBL] [Abstract][Full Text] [Related]
7. Reference intervals in Danish children and adolescents for bone turnover markers carboxy-terminal cross-linked telopeptide of type I collagen (β-CTX), pro-collagen type I N-terminal propeptide (PINP), osteocalcin (OC) and bone-specific alkaline phosphatase (bone ALP).
Diemar SS; Lylloff L; Rønne MS; Møllehave LT; Heidemann M; Thuesen BH; Johannesen J; Schou AJ; Husby S; Wedderkopp N; Mølgaard C; Jørgensen NR
Bone; 2021 May; 146():115879. PubMed ID: 33561588
[TBL] [Abstract][Full Text] [Related]
8. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
9. Bone Metabolism and RANKL/OPG Ratio in Rheumatoid Arthritis Women Treated with TNF-α Inhibitors.
Jura-Półtorak A; Szeremeta A; Olczyk K; Zoń-Giebel A; Komosińska-Vassev K
J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34209821
[TBL] [Abstract][Full Text] [Related]
10. Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood.
Bhattoa HP; Cavalier E; Eastell R; Heijboer AC; Jørgensen NR; Makris K; Ulmer CZ; Kanis JA; Cooper C; Silverman SL; Vasikaran SD;
Clin Chim Acta; 2021 Apr; 515():16-20. PubMed ID: 33382995
[TBL] [Abstract][Full Text] [Related]
11. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.
Szulc P; Naylor K; Hoyle NR; Eastell R; Leary ET;
Osteoporos Int; 2017 Sep; 28(9):2541-2556. PubMed ID: 28631236
[TBL] [Abstract][Full Text] [Related]
12. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
[TBL] [Abstract][Full Text] [Related]
13. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
[TBL] [Abstract][Full Text] [Related]
14. Restricted Mean Survival Time-Can It Be a New Tool in Assessing the Survival of Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors?
Pîrlog CF; Costache R; Paroșanu AI; Slavu CO; Olaru M; Popa AM; Iaciu C; Niță I; Moțatu P; Cotan HT; Oprița AV; Costache D; Manolescu LSC; Nițipir C
Diagnostics (Basel); 2023 May; 13(11):. PubMed ID: 37296744
[TBL] [Abstract][Full Text] [Related]
15. The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer.
Hadji P; Ziller M; Maurer T; Autenrieth M; Muth M; Ruebel A; May C; Birkholz K; Diebel E; Gleissner J; Rothe P; Gschwend JE
J Bone Oncol; 2012 Dec; 1(3):88-94. PubMed ID: 26909262
[TBL] [Abstract][Full Text] [Related]
16. Reference intervals for serum concentrations of three bone turnover markers for men and women.
Michelsen J; Wallaschofski H; Friedrich N; Spielhagen C; Rettig R; Ittermann T; Nauck M; Hannemann A
Bone; 2013 Dec; 57(2):399-404. PubMed ID: 24076251
[TBL] [Abstract][Full Text] [Related]
17. Bone Turnover Markers Are Not Associated With Hip Fracture Risk: A Case-Control Study in the Women's Health Initiative.
Crandall CJ; Vasan S; LaCroix A; LeBoff MS; Cauley JA; Robbins JA; Jackson RD; Bauer DC
J Bone Miner Res; 2018 Jul; 33(7):1199-1208. PubMed ID: 29923225
[TBL] [Abstract][Full Text] [Related]
18. Effect of cachexia on bone turnover in cancer patients: a case-control study.
Zwickl H; Zwickl-Traxler E; Haushofer A; Seier J; Podar K; Weber M; Hackner K; Jacobi N; Pecherstorfer M; Vallet S
BMC Cancer; 2021 Jun; 21(1):744. PubMed ID: 34182958
[TBL] [Abstract][Full Text] [Related]
19. The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer.
Asano Y; Yamamoto N; Demura S; Hayashi K; Takeuchi A; Kato S; Miwa S; Igarashi K; Higuchi T; Yonezawa H; Araki Y; Morinaga S; Saito S; Sone T; Kasahara K; Tsuchiya H
Front Oncol; 2022; 12():871675. PubMed ID: 35433422
[TBL] [Abstract][Full Text] [Related]
20. Age-related trends and reference intervals of cross-linked C-telopeptide of type I collagen and procollagen type I N-propeptide from a reference population of Sri Lankan adult women.
Rathnayake H; Lekamwasam S; Wickramatilake C; De Zoysa E; Lenora J
Arch Osteoporos; 2021 Nov; 16(1):164. PubMed ID: 34727246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
